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A B S T R A C T
Background: Resistant hypertension is a well-recognized clinical challenge yet there are no reported data
on its prevalence in Pakistan. These patients are subjected to a higher risk of developing hypertensive
complications. The objective of our study was to evaluate the prevalence and determinants of resistant
hypertension in an Asian cohort of hypertensive patients.
Methods: This cross-sectional study was carried out among hypertensive patients visiting a tertiary care
hospital in Karachi fromSeptember-December 2015. Patient data and characteristicswere recorded using
a pre-coded questionnaire. Morisky and Berlin questionnaires were used to assess compliance to
medications and determine the risk of developing obstructive sleep apnea, respectively. Pearson's chi-
square test was used to analyze statistical differences between hypertensive patients and related factors.
Results: A total of 515 patients were included in the study. Overall, 12% of the total patients (n =62) were
resistant hypertensives and 25% (n =129) had pseudo-resistant hypertension. Resistant patients were
more often females, older and had a higher body mass index (all P<0.001). Use of painkillers and
noncompliance to dietary recommendations were found to be significant determinants of resistant
hypertension. Prevalence of comorbid conditions, including diabetes (p =0.33), hyperlipidemia (p =0.46),
and chronic kidney disease (p =0.23), was not significantly higher in patientswith resistant hypertension.
Conclusion: Nearly one in ten hypertensive patients had true resistant hypertension, and twenty-five
percent of patients had pseudo-resistance. Resistance hypertensions is significantly associated with
female gender, older age, obesity, dietary noncompliance and increased use of NSAIDs.
© 2017 Published by Elsevier B.V. on behalf of Cardiological Society of India. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Hypertension is one of the most important risk factors for
cardiovascular and renal diseases. Approximately 1 billion adults
have hypertension and the prevalence is increasing.1 Despite best
efforts to control blood pressure, resistant hypertension (RH) may
occur.2 In spite of increased recognition and therapeutic inter-
ventions, studies show that the efficiency of blood pressure control
in hypertensive patients continues to decline,1,3,4 with an increase
in the incidence of RH worldwide.5–8 The failure to achieve target
values of blood pressure has several causes such as poor treatment
adherence, scarcity of resources and failure to intensify treatment
in a timely manner.9
Nearly 1/5th of the population of Pakistan suffers from
hypertension with prevalence expected to rise in the coming
years.10 However, RH prevalence values have yet to be reported.
Despite an increase in the number of clinical studies on the
prevalence of RH, the growing incidence of this condition among
treated hypertensive patients is established to be between 5 and
30% in the developed part of the world.2,4,10–12 This disparity is
primarily because of the difference in definition employed in the
study or failure to rule out pseudo-hypertension. There is a dearth
of published literature providing up-to-date estimates of the
prevalence of RH across developing regions of the world.
* Corresponding author at: 259/3, falcon complex faisal,[34_TD$DIFF] Karachi, 75350, Pakistan.
E-mail address: rabianaseemm@gmail.com (R. Naseem).
http://dx.doi.org/10.1016/j.ihj.2017.01.012
0019-4832/© 2017 Published by Elsevier B.V. on behalf of Cardiological Society of India. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
Indian Heart Journal 69 (2017) 442–446
Contents lists available at ScienceDirect
Indian Heart Journal
journal homepage: www.elsevier .com/ locate / ih j
Existing researches have, hitherto, mainly focused on Western
population while the prevalence of RH in South Asia has not been
well explored. Therefore, these RH prevalence estimatesmay differ
fromwhatwould be found in amiddle-incomemetropolis like that
of Karachi.
An interesting development is the proof offered by prevalence
surveys and genome-wide association studies that the incidence of
hypertension and its resistant category has a genetic component
and predisposes population of South Asians and Central and
Eastern.13–15 However, the disease remains idiopathic in its
essence, with its proximal causes still not well defined.16
Defining optimal treatment for patients with RH is a clinical
challenge. Hence, a greater understanding of this subgroup of
hypertensive patients is crucial for establishing known determi-
nants and facilitate the development of targeted strategies for
prevention, treatment, and control. Thus, the objective of our study
was to assess the prevalence and predictors of resistant
hypertension in an Asian cohort of hypertensive patients.
2. Method
This cross-sectional study was conducted at a tertiary care
hospital in Karachi, Pakistan for a duration of four months from
September 1, 2015 to December 31, 2015. It consisted of a survey of
all patients older than 18 years, previously diagnosed with
essential hypertension, who had records of 3 or more blood
pressuremeasurementswithin the past one year, presenting to the
clinics. Essential hypertension was defined as a systolic blood
pressure that is persistently140mmHg on 2 or more occasions,
or a diastolic blood pressure persistently90mmHg on 2 or more
occasions, when an average of each is measured at every visit using
at least 2 values.17 Patients whowere known cases of hypertension
secondary to tumors or other diseases of the endocrine system,
obesity, pregnancy, coarctation of aorta, and use of hormonal
contraceptives were excluded from the study. The study was
approved by the Institutional Review Board of Dow University of
Health Sciences (DUHS)
Participants were selected via convenience sampling; all
patients visiting the clinic on a given day were interviewed after
written consent. Participant cooperation rate was 96%, which
yielded a total of 515 complete cases for analyses. For the purpose
of this study, we used a pilot-tested questionnaire that was
administered to each patient with the help of an interviewer.
Moreover, interviewer bias was eliminated by training inter-
viewers who were kept unaware of the outcome of interest for the
study. From each patient, we obtained information on socio-
demographic details, duration of hypertension, current medica-
tions, co-morbid conditions, lifestyle and family history of
hypertension. In addition to these, Berlin questionnaire was used
to determine the risk of developing obstructive sleep apnea (OSA),
dividing the patients into high and low-risk categories. Morisky
questionnairewas utilized to assess adherence to antihypertensive
medications, the results of which were classified into high, average
and poor adherence, following which all cases of RH were further
classified into those with pseudo-resistance and those with true
resistant hypertension. True resistant hypertension (tRH) was
defined as blood pressure that exceeds target values in spite of best
possible regimen consisting of 3 antihypertensive drugs of
different classes, where one should ideally be a diuretic.18
Pseudo-resistance was defined as uncontrolled hypertension as
a result of inaccurate measurement, poor adherence to prescribed
medications, incorrect drug choices/doses, or white-coat effect.19
Moreover, to measure blood pressure (BP) of each patient, the
physician used a mercury sphygmomanometer. After an initial
resting period of 5 [35_TD$DIFF][30_TD$DIFF]minutes, twomeasurementswere takenwith an
interval of 10min in between, andmean values of both systolic and
diastolic blood pressure were recorded. In addition to these, 3
previous blood pressure values were extracted from the patients’
files. WHO defines a BMI25kg/m2 as overweight, whereas
obesity is categorized as BMI30 kg/m2.20
For the purpose of this study, all data entry and analyses were
done using the IBM Statistical Package for Social Sciences (SPSS),
version 23 for Windows. Frequencies with percentages were
calculated for all categorical variables and the Chi-square test was
used to check the significance of relationships between character-
istics of patients with essential hypertension and those with true
resistant hypertension. No imputation methods were used to
replace missing values, and only completely filled questionnaires
were considered for our use. A p-value of less than 0.05 was
considered to be significant.
3. Results
The mean age of patients was 64.312.3 years, with a mean
BMI of 29.14.5 kg/m2. The mean systolic and diastolic blood
pressures were 14215.2mmHg and 8811.7mmHg, respective-
ly. More than half the patients had diabetes mellitus (n = 287,
55.7%), while 78 patients (15.1%) had a positive family history for
hypertension. Approximately a third of the total patients (n =174,
33.8%) were non-compliant to dietary recommendations. It was
found that patients were (n = 317, 61.6%) moderately adherent to
prescribed antihypertensive medications. Among the sample
cohort, 112 patients (21.7%) were at a high risk of developing
OSA. Table 1 summarizes the baseline characteristics of the sample
population.
Prevalence of true resistant hypertensionwas low (n=62, 12%),
a quarter (n = 129, 25%) of the population were pseudo-resistant
hypertensive patients while most (n = 320; 63%) had essential
hypertensionwith no form of RH (Fig.1). The study populationwas
divided into two groups according to patients exhibiting essential
Table 1
Baseline characteristics of patients.
Characteristics
Male, n (%) 309 (60.0)
Married, n (%) 463 (89.9)
Average systolic blood pressure, mmHg 14215.2
Average diastolic blood pressure, mmHg 8811.7
Mean BMI, (kg/m2) 29.14.5
Drugs, n (%)
Steroids 33 (6.4)
Painkillers 171 (33.2)
Lifestyle risk factors, n (%)
Dietary non-compliance 174 (33.8)
Smoking 194 (37.7)
Alcohol 26 (5.0)
Co-morbidities, n (%)
Diabetes Mellitus 287 (55.7)
Hyperlipidemia 114 (22.1)
Chronic kidney disease 39 (7.6)
Family history, n (%)a 78 (15.1)
Adherence, n (%)b
High 151 (29.3)
Average 317 (61.6)
Poor 47 (9.1)
Risk of OSA, n (%)c
High 112 (21.7)
Low 403 (78.3)
a Patients with positive family history for hypertension.
b Adherence to prescribed antihypertensive agents.
c Obstructive sleep apnea.
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hypertension (n =453) and true resistant hypertension (n =62).
The comparison of different characteristics is seen in Table 2. The
resistant population was significantly older (66.1% vs 21.2;
p<0.001), a greater proportion was female (80.6% vs 34.4%;
p<0.001) and was associated (58.1% vs 16.8; p<0.001) with
obesity (BMI 30 kg/m2) when compared to the non-RH popula-
tion. Similarly, in comparison to those with non-RH, patients with
RH were associated with OSA (53.2% vs 17.4%; p<0.001) and the
use of painkillers (45.2% vs 31.6%; p =0.033) was significantly
higher. A significant proportion of patients (n =37, 59.7%; p = 0.004)
with RHwere non-compliant to the dietary recommendations. The
prevalence of diabetes mellitus (p = 0.33), chronic kidney disease
(p = 0.23) and hyperlipidemia (p = 0.46) was not statistically
significant between the two groups.
4. Discussion
The prevalence of RH among our study populationwas 12%. This
finding is consistent with other observational studies,4,21,22
however it is still lower than several studies conducted in Europe
and North America. A possible reason for the lower prevalence of
RH could be the different conditions of our study. In the Controlled
Onset Verapamil Investigation of Cardiovascular Endpoints trial,
the prevalence of RH was 18%.23 In this study, data was collected
from patients who were 55 years or older and had additional
cardiovascular risk factors. However, our study includes all
hypertensive patients older than 18 years of age with no strict
inclusion criteria for cardiovascular risk factors. Prior studies have
often also over-estimated tRH without ruling out pseudo-resis-
tance.4,18 In our study, a quarter of the total patients were pseudo-
resistant hypertensives. A phenomenon that can be caused by
various factors, including inaccurate measurement of BP, poor
adherence or suboptimal treatment regimens, physician’s inertia
or white-coat effect, produces a false impression of tRH if not taken
into account.7 The incapacity of ruling out pseudo-resistance is a
matter of great importance in order to avoid over treatment and
avoid complications. Despite the increased recognition of the high-
risk associated with the condition, cases with RH have been poorly
characterized in literature especially in South Asian countries
including Pakistan. The limited data that could be gathered from
the studies conducted in our neighboring countries show that the
prevalence of RH is on a steady rise.10,14,16 According to Daugherty
et al., approximately 1 in 6 patients on 3 or more antihypertensive
drugs will continue to meet the criteria for RH after 1 year.6
Physicians can expect to encounter RH one in every ten
hypertensive patients on treatment. This situation is worrisome
and highlights that treatment resistant BP will continue to be a
clinically important hypertension phenotype.
Our results also show that patients above 65 were significantly
more likely to develop RH, a trend which has been observed in
most epidemiological studies.22,23 A study carried on hypertensive
patients reported that prevalence of RH increased with age,
particularly in females as compared tomales; implying that gender
and age may be used to predict development of RH.22 Parallel to
this observation, the Framingham study data identified old age as
the strongest predictor of tRH.24 Itmay be attributed to age-related
changes in blood vessels and an increase in frequency of all related
conditions (e.g., obesity, diabetesmellitus, CKD).Moreover, we also
observed a significant association with the female gender. Several
studies have reported sexual dimorphism in BP such that incidence
of hypertension is much higher in males during early adulthood,
but this level alters after the sixth decade of life. The rise in the BP
after the age of 55 is steeper in females as compared to males,
which also shows features of treatment resistance.18,25,26 Women
are more likely to have difficulty adhering to optimum BP, have a
higher prevalence of co-morbidities and obesity influenced by
estrogen withdrawal and, as a consequence, are more likely to
develop RH.
A statistically significant relationship was associated between
obesity and RH in our study;more than half of the patients with RH
were obese while only one-fifth of those with essential hyperten-
sion had BMI > 30, kg/m2. Obesity, the sixth most important
predisposing factor for RH,27 elevates the need for increased
number of antihypertensive medications and also increases
tendency of never achieving required BP control.28 Increased
body weight predisposes to tRH by causing decreased sodium
excretion, insulin resistance, increased activity of sympathetic
nervous system and lastly renal injury by the activation of the
renin-angiotensin system.29 The obesity pandemic poses a
substantial threat to society and propermeasures towards lifestyle
modification, including low fat diet and routine exercises, can help
reduce the incidence of RH.
In our study, dietary non-compliance had a significant impact
on RH exemplifying the role of adequate diet in hypertension
prevalence, which has been long recognized and established across
numerous studies. Previous literature suggests high salt diet as the
main culprit causing resistance to antihypertensive agents. This
may occur by increment of BP or by blunting the BP-lowering effect
of antihypertensive agents.27–32 Resistant hypertensive patients
[(Fig._1)TD$FIG]
25%
12%63%
Pseudo-resistant hypertension
True resistant hypertension
Essential hypertension only
Fig. 1. Distribution of patients with hypertension.
Table 2
Comparison of characteristics between patients with true resistant hypertension and essential hypertension.
Essential Hypertension (n = 453, %)a True Resistant Hypertension (n = 62, %) p-valueb
Males 297 (65.6) 12 (19.3) <0.001
Age >65, years 96 (21.2) 41 (66.1) <0.001
BMI >30, kg/m2 76 (16.8) 36 (58.1) <0.001
Dietary non-compliance 137 (30.2) 37 (59.7) 0.004
Alcohol 21 (4.64) 5 (8.06) 0.25
High risk of OSA c 79 (17.4) 33 (53.2) <0.001
Diabetes 256 (56.5) 31 (50.0) 0.33
Hyperlipidemia 98 (21.6) 16 (25.8) 0.46
Chronic kidney disease 32 (7.03) 7 (11.3) 0.23
Painkillers 143 (31.6) 28 (45.2) 0.033
a Patients who do not have true resistant hyperension.
b p-values <0.05 were considered statistically significant.
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tend to exhibit a higher salt sensitivity as compared to patients
with essential hypertension.14 This may be due to the use of renin-
angiotensin system blockers, as a part of the treatment regime,
which heighten the hypertensive response to high salt intake.6,25
Therefore, it is important to understand that dietary noncompli-
ance can negate or nullify the effect of even the most ideal drug
therapy.33 Other dietary factors such as high potassium intake,
vegetarian diet and cessation of tobacco smoking have also been
reported to be involved in BP control.34 However, these dietary
conditions are less likely to be adopted by the younger age group
(<65years). Regular family meals at home are infrequent in this
group instead they are more likely to consume fast-food on a
regular basis with friends and family, ultimately leading to an
increase in the intake of oily, salty food, which in general could
adversely affect people of all age groups. Given the strong
relationship, adequate BP control is paramount. Proper counseling
may largely contribute to resolving noncompliance along with
monitoring andmoral support by familymembers. In addition, the
use ofwritten instructions and pictograms have also proved to play
an elementary role in patients’ dietary compliance.35,36
Interestingly, our study did not find a significant relationship
between chronic kidney disease and RH. This finding is at oddswith
previous epidemiological studies,4,6,11,13 identifying renal disease
bothasacauseandconsequenceofRH. It is reasonabletoassumethat
the small sample size drawn from a single tertiary care center may
have excluded patients with chronic kidney disease who may have
been referred to the nephrology clinic. The number of patients with
previously existing renal disease was also moderately low. Mecha-
nisms involving sodium and fluid retention, activation of the renin–
angiotensin–aldosterone hormonal axis could plausibly account for
the reported rise in treatment resistance.
Another important finding of this study is the evaluation of OSA
in patients with RH compared to those with essential hyperten-
sion. RH was associated with a significantly increased risk of
developing OSA. The intermittent cessation in airflow may cause
hypoxia leading to the release of endothelin from vascular
endothelium ultimately causing vasoconstriction. These cyclical
changes in the levels of endothelin and repeated oxygen
desaturation leads to the development of RH.37 Logan AG et al.,
evaluated 41 consecutive patients with t-RH of which 83% patients
suffered from unsuspected sleep apnea.38 However, a study
conducted by Min HJ et al. concluded that the potential causal
association between OSA and hypertension is in fact due to
common risk factors, primarily obesity, between the two
conditions.39 Patients with OSA may also be at increased risk for
weight gain. Therefore, physiciansmust not disregard correction of
risk factors in the treatment of RH patients.
Our results raise the prospect that an increased use of
painkillers contributes to the poor control found in RH. Given
the widespread use of non-narcotic analgesics including the
NSAIDs, aspirin and acetaminophen they are most likely the
offending agents concerning BP control40,41; their role well
established in literature.42,43 We believe that the number of
people who took excessive painkillers for controlling their
respective pains were not aware of the side effects of these drugs
and their role in decreasing the efficacy of the BP controlling
medications. In addition, other painkillers, like acetaminophen,
have been found to develop hypertension,41 but in comparison to
NSAIDS (particularly ibuprofen), are less likely to worsen BP
control in treated patients.42 Thus, such medications should be
avoided or withdrawn in resistant hypertensive patients. As this
may be clinically difficult, the lowest effective dose should be
administered when needed.
We could not find any association between diabetes mellitus
and resistant hypertension. This observation is discordant with
other previous studies which have shown a positive relation.11,22 A
possible reason could be because of our small sample size of
patients. Moreover, it could also be due to an overall high
prevalence of diabetes mellitus in the existing sample; more than
half of the patients were diabetic.
There are several limitations in our study which need to be
considered. First, we collected data from a single tertiary care
hospitalyieldingasmallsizeofpatients;howeverRHprevalence is in
linewith previous reports. Second, the cross-sectional design of our
study limits the inference of reasons related for development of the
identified risk factors and isdesigned to suggest associationonlyand
does not assess causality. Therefore, it is important to conduct
prospective studies in order to determine antecedent factors
associated with the predisposition of RH. Third, we employed
convenience sampling in our study. Since data was collected in
accordance to the convenience of the interviewers, this might have
neglected some people with RH visiting the hospital on other days.
We also relied on patient’s self-reporting for compliance to
antihypertensive medications and dietary intake as it was feasible
and cost effective. Lastly, patients in the study were spread over a
wide age range accounting for significant differences and the
findings should thus be generalized with caution. We believe
consideration of these important points can help better understand
the key role players in the development, progression and prognosis
of RH.
5. Conclusion
The prevalence of RH is on a road to rise and has the potential of
becoming a major problem in the upcoming years, imposing a
heavy social and economic burden on the country. Attention to
metabolic risk factors, reinforcing lifestyle modifications and
avoiding agents that can elevate the BP, may be the key. Although
the results need to be confirmed by prospective studies evaluating
the relationship between the aforementioned risk factors and
delineating pathogenesis and interventional studies investigating
the role of diagnostic evaluation; they do establish that early
identification is prudent.
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